{"id":"ssri-venlafaxine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Insomnia"},{"rate":"5-10%","effect":"Sweating"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201066","moleculeType":"Small molecule","molecularWeight":"313.87"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the reuptake of serotonin and norepinephrine, venlafaxine increases the concentration of these neurotransmitters in the synaptic cleft, which can help alleviate symptoms of depression and anxiety. This is thought to occur through the inhibition of the serotonin and norepinephrine transporters, leading to increased synaptic levels of these neurotransmitters.","oneSentence":"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:01.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT07161492","phase":"NA","title":"A Study on Functional Connectome and rTMS Intervention of Cognitive Flexibility Impairment in Patients With Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2025-09","conditions":"Depressive Disorder, Major, Cognitive Impairment","enrollment":182},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT05830279","phase":"","title":"Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2023-05-01","conditions":"Nausea With Vomiting Chemotherapy-Induced, Depression, Reactive, Cancer Pain","enrollment":600},{"nctId":"NCT04973930","phase":"PHASE3","title":"Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer","status":"SUSPENDED","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Major Depressive Disorder, Breast Cancer, Venlafaxine","enrollment":20},{"nctId":"NCT04597190","phase":"PHASE4","title":"Sequenced Treatment Effectiveness for Posttraumatic Stress","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-06-01","conditions":"PTSD","enrollment":700},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":"Major Depressive Disorder","enrollment":73336},{"nctId":"NCT04748276","phase":"","title":"Tracking Response to Antidepressants in Advance of Investigational Trials","status":"UNKNOWN","sponsor":"Adams Clinical","startDate":"2019-01-02","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT03464383","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Treatment Study","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-07","conditions":"Anxiety, Depression, Epilepsy","enrollment":69},{"nctId":"NCT03274817","phase":"PHASE1","title":"A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2009-06-18","conditions":"Alzheimer Disease","enrollment":5},{"nctId":"NCT03522987","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Pilot Treatment Study","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05","conditions":"Anxiety, Depression, Epilepsy","enrollment":""},{"nctId":"NCT00043550","phase":"PHASE3","title":"Treatments for Depression: Drug Versus Psychotherapy","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2001-11","conditions":"Depression","enrollment":156},{"nctId":"NCT00211809","phase":"PHASE4","title":"CBT as an Adjunct to SRIs in the Treatment of BDD","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2008-09","conditions":"Body Dysmorphic Disorder","enrollment":17},{"nctId":"NCT02476136","phase":"","title":"Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis","status":"UNKNOWN","sponsor":"prof. Peter de Jonge","startDate":"2015-05","conditions":"Anxiety Disorders, Panic Disorder, Obsessive-compulsive Disorder","enrollment":8800},{"nctId":"NCT02873234","phase":"","title":"A Study of Chinese Medicine Treating Depression","status":"UNKNOWN","sponsor":"The Third Affiliated Hospital of Beijing University of Chinese Medicine","startDate":"2016-06","conditions":"Depression","enrollment":4600},{"nctId":"NCT02320240","phase":"","title":"Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2013-06","conditions":"Depression, Acute Kidney Injury","enrollment":3255526},{"nctId":"NCT00817375","phase":"NA","title":"Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2003-02","conditions":"Depression, Adverse Reaction to Drug","enrollment":1000},{"nctId":"NCT00817011","phase":"NA","title":"Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2006-04","conditions":"Depression, Antidepressant Drug Adverse Reaction","enrollment":1000},{"nctId":"NCT01228357","phase":"NA","title":"Predict Antidepressant Responsiveness Using Pharmacogenomics","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2003-02","conditions":"Depression, Depressive Symptoms","enrollment":1000},{"nctId":"NCT01796132","phase":"PHASE4","title":"Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2012-08","conditions":"Depressive Disorder, Lactation","enrollment":500},{"nctId":"NCT00129467","phase":"NA","title":"Methylphenidate for Depressed Cancer Patients Receiving Palliative Care","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-02","conditions":"Depression, Palliative Care, Cancer","enrollment":47},{"nctId":"NCT01436643","phase":"PHASE4","title":"Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Depression, Relapsing-remitting Multiple Sclerosis","enrollment":54},{"nctId":"NCT00074815","phase":"PHASE3","title":"Treatment of Obsessive Compulsive Disorder in Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-09","conditions":"Obsessive-Compulsive Disorder","enrollment":124},{"nctId":"NCT00590863","phase":"PHASE4","title":"Combining Medications to Enhance Depression Outcomes","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-03","conditions":"Major Depressive Disorder","enrollment":665},{"nctId":"NCT00167856","phase":"NA","title":"Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-06","conditions":"Neuropathic Pain, Pain, Spinal Cord Injuries","enrollment":16},{"nctId":"NCT00018902","phase":"PHASE2, PHASE3","title":"Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2001-01","conditions":"Depression","enrollment":334},{"nctId":"NCT00944996","phase":"NA","title":"Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression","status":"COMPLETED","sponsor":"Tirat Carmel Mental Health Center","startDate":"2009-06","conditions":"Major Depression","enrollment":100},{"nctId":"NCT00789854","phase":"PHASE3","title":"Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Major Depressive Disorder, Treatment Resistant Depression","enrollment":688},{"nctId":"NCT00474708","phase":"PHASE4","title":"Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Major Depressive Disorder","enrollment":1151},{"nctId":"NCT00763724","phase":"","title":"Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-06","conditions":"Depression, Suicide","enrollment":254432},{"nctId":"NCT00782964","phase":"","title":"Antidepressant Incomplete Response Depression","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Major Depressive Disorder","enrollment":364},{"nctId":"NCT00745017","phase":"PHASE1","title":"Stress Generation and Recurrent Depression: The Role of Differential Treatment Response","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2001-07","conditions":"Depression, Major Depressive Disorder","enrollment":72},{"nctId":"NCT00744406","phase":"PHASE2","title":"Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2003-07","conditions":"Depression, Major Depressive Disorder","enrollment":72},{"nctId":"NCT00157547","phase":"PHASE4","title":"Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-04","conditions":"Major Depressive Disorder","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SSRI/Venlafaxine","genericName":"SSRI/Venlafaxine","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}